These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 24176011)

  • 1. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
    Tanaka H; Hayashi S; Hoshi H
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
    Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT).
    Takeda A; Yokosuka N; Ohashi T; Kunieda E; Fujii H; Aoki Y; Sanuki N; Koike N; Ozawa Y
    Radiother Oncol; 2011 Nov; 101(2):291-7. PubMed ID: 21889224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.
    Takeda A; Sanuki N; Fujii H; Yokosuka N; Nishimura S; Aoki Y; Oku Y; Ozawa Y; Kunieda E
    J Thorac Oncol; 2014 Jan; 9(1):65-73. PubMed ID: 24346094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.
    Um SW; Kim H; Koh WJ; Suh GY; Chung MP; Kwon OJ; Choi JY; Han J; Lee KS; Kim J
    J Thorac Oncol; 2009 Nov; 4(11):1331-6. PubMed ID: 19701106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognositc significance of SUV
    Dong M; Liu J; Sun X; Xing L
    J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
    Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A SUV
    Ye L; Xu F; Shi S; Zeng Z; Jin X; Huang Y; Lu C; Gu J; Ge D; He J
    Clin Transl Oncol; 2018 Aug; 20(8):1026-1034. PubMed ID: 29327241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
    Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
    Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D; Gill S; Loh N
    Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
    Goodgame B; Pillot GA; Yang Z; Shriki J; Meyers BF; Zoole J; Gao F; Dehdashti F; Patterson A; Siegel BA; Govindan R
    J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
    Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
    Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.